Abstract:Objective To evaluate the clinical curative effect and safety of different doses of calf pulmonary surfactant in the treatment of premature infants with respiratory distress syndrome. Methods The premature infants with respiratory distress syndrome were treated with three different doses of calf pulmonary surfactant. 93 cases met the inclusive criteria among the whole cases. There were 31 cases treated with small doses of calf pulmonary surfac-tant (40-70mg/kg), 31 cases treated with middle doses of calf pulmonary surfactant (70-100 mg/kg) and 31 ca-ses treated with large doses of calf pulmonary surfactant (100-140mg/kg). The results of blood gas analysis were compared among the three groups before and after treatment, including pH, arterial oxygen tension and arterial carbon oxygen tension. Other items of comparison included sex, gestational age, birth weight, cesarean section, Apgar scores, amniotic fluid, need for repeated drug use, need for mechanical ventilation, duration of mechanical ventila-tion, duration of oxygen therapy, duration of hospital stay, outcomes, complications and average hospital expenses. Results There was no significant difference in sex, gestational age, birth weight, cesarean section, Apgar scores, amniotic fluid and premature rupture of membranes among the three groups (P>0. 05). 6 hours after the first appli-cation of pulmonary surfactant, the pH value and the arterial oxygen tension of the whole infants increased in varying degrees, and the arterial carbon oxygen tension of the whole infants decreased in varying degrees ( P<0. 05 ) . The differences of pH value, arterial oxygen tension and arterial carbon oxygen tension among the three groups had no sta-tistical significance before the treatment ( P >0. 05 ) . The difference of the curative effect among the three groups ( including the need for repeated drug use, the need for mechanical ventilation, the duration of mechanical ventilation and the duration of oxygen therapy) had no statistical significance (P>0. 05). There was no significant difference in complication morbidity and the cure rate among the three groups (P>0. 05), but it showed significant differences in the average hospital expenses and the average duration of hospital stay among the three groups ( P<0. 05 ) . Com-pared with the large dose group, the average hospital expenses in the middle dose group decreased. And compared with the small dose group, the average duration of hospital stay in the middle dose group decreased. Conclusion The clinical curative effect and safety of the three doses of calf pulmonary surfactant are analogous in the treatment of premature infants with respiratory distress syndrome. But the average hospitalization expenses in the middle doses group is less than that of the large doses groups, and the average duration of hospitalization in the middle dose group is less than that of the small doses group.

In Vitro Characterization and in Vivo Comparison of the Pulmonary Outcomes of Poractant Alfa and Calsurf in Ventilated Preterm Rabbits

Treatment of Severe Meconium Aspiration Syndrome with Porcine Surfactant: A Multicentre, Randomized, Controlled Trial

Comparison of the effect of Calsurf and Curosurf in treating respiratory distress syndrome of preterm infants

Comparative biophysical study of clinical surfactants using constrained drop surfactometry

New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs

Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits.

Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits

[The Influence of Surfactant on the Alveolar Morphology in Premature Rabbits].

Comparison of Effects of Surfactant and Inhaled Nitric Oxide in Rabbits with Surfactant-Depleted Respiratory Failure.

Efficacy, dose-response, and aerosol delivery of dry powder synthetic lung surfactant treatment in surfactant-deficient rabbits and premature lambs

Observation on the Clinical Curative Effect of Different Doses of Calf Pulmonary Surfactant in the Treatment of Premature Infants with Respiratory Distress Syndrome

Comparison of porcine versus bovine surfactant in preterm respiratory distress syndrome: Evidence from real‐world data. A multicentre collaboration from Karnataka

Combined Surfactant Therapy and Inhaled Nitric Oxide in Rabbits with Oleic Acid-induced Acute Respiratory Distress Syndrome

Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model

Comparative Study for Influence on Neonatal Respiratory Distress Syndrome between Different Pulmonary Surfactants

Effects of Various Forms of Surfactant Protein C on Tidal Volume in Ventilated Immature Newborn Rabbits.

Effects of hyaluronan-fortified surfactant in ventilated premature piglets with respiratory distress.

Application of a New Ventilator-Multi-plethysmograph System for Testing Efficacy of Surfactant Replacement in Newborn Rabbits

Prevention of Rabbit Acute Lung Injury by Surfactant, Inhaled Nitric Oxide, and Pressure Support Ventilation

A Combination of Short and Simple Surfactant Protein B and C Analogues as a New Synthetic Surfactant: In Vitro and Animal Experiments

Breath-Synchronized Nebulized Surfactant in a Porcine Model of Acute Respiratory Distress Syndrome